Status:
COMPLETED
Growth Hormone Therapy in Liver Cirrhosis
Lead Sponsor:
Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions:
Cirrhosis, Liver
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
PHASE3
Brief Summary
Liver cirrhosis (LC) is a leading cause of morbidity and mortality worldwide. Life- threatening complications of liver cirrhosis are ascites, gastrointestinal bleeding, variceal bleed, hepatic encepha...
Eligibility Criteria
Inclusion
- Decompensated Cirrhosis of liver irrespective of etiology
Exclusion
- Acute on chronic liver failure (fulfilling either APASL or CANONIC criteria of ACLF)
- Splenic diameter of more than 18 cm
- Concomitant HCC or other active malignancy
- Upper gastrointestinal bleeding in the previous 7 days
- Portal vein thrombosis
- Severe renal dysfunction as defined by creatnine \> 1.5mg/dl
- Severe cardiac dysfunction
- Uncontrolled diabetes (Hb A 1c ≥ 9) or diabetic retinopathy
- Acute infection or disseminate intravascular coagulation
- Active alcohol abuse in last 3 months
- Known hypersensitivity to GH
- HIV co-infection
- Pregnancy
- Refusal to give informed consent
Key Trial Info
Start Date :
January 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT03420144
Start Date
January 15 2018
End Date
June 30 2020
Last Update
May 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Post Graduate Institute of Medical Education and Research
Chandigarh, India, 160012